SequelSEC

VivoSim Labs, INC. VIVS

Biological Products, (No Diagnostic Substances) · CIK 0001497253 · Fiscal year ends 0331

Revenue
$131.00K
Fiscal year ended 2026-03-31
Operating income
-$11.49M
Fiscal year ended 2026-03-31
Free cash flow
-$10.83M
Fiscal year ended 2026-03-31

VivoSim Labs, INC. (VIVS) reported revenue of $131.00K and net income of -$13.84M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VivoSim Labs, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

VivoSim Labs, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Revenue$131.00K$144.00K$109.00K$370.00K$1.50M$0$2.20M$3.09M$4.60M$4.23M
Cost of revenue$0$5.00KUnavailableUnavailableUnavailable$0$300.00K$500.00K$1.00M$956.00K
Gross profit$131.00K$139.00KUnavailableUnavailableUnavailableUnavailable$1.90M$2.59M$3.60M$3.27M
Operating income-$11.49M-$12.62M-$15.09M-$17.73M-$11.48M-$16.83M-$21.48M-$27.27M-$35.27M-$38.58M
Net income-$13.84M-$2.49M-$14.67M-$17.26M-$11.45M-$16.83M-$18.71M-$26.64M-$34.80M-$38.45M
Research & development$4.19M$5.02M$5.50M$8.88M$3.32M$1.10M$5.28M$14.75M$17.96M$19.54M
Weighted-average diluted sharesshares 2.59Mshares 1.46MUnavailableshares 8.71Mshares 8.70MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$13.84M-$2.49MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$2.00K$2.00K$2.00K$2.00K$2.00K$2.00K$2.00K$3.00K$2.00K$23.00K
Diluted EPS$-5.35$-1.70$-19.25$-1.98$-1.32UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$7.43M$7.73M$9.70M$9.22M$9.66M$15.72M$18.06M$15.13M$20.89M$22.30M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VivoSim Labs, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Cash & equivalents$5.02M$11.31M$2.90M$15.30M$28.68M$37.36M$27.36M$36.48M$43.73M$62.75M
Total assets$7.39M$14.65M$6.35M$20.31M$33.30M$39.92M$28.44M$40.62M$49.83M$69.18M
Current assets$6.63M$12.13M$3.94M$17.05M$29.53M$38.40M$28.32M$38.57M$46.76M$65.09M
Total liabilities$8.48M$4.16M$2.75M$4.98M$3.09M$721.00K$1.81M$4.32M$5.24M$6.82M
Current liabilities$2.78M$3.74M$1.86M$3.67M$1.38M$721.00K$1.81M$3.74M$4.66M$6.01M
Total equity incl. NCI-$1.10M$10.49M$3.60M$15.33M$30.21M$39.20M$26.63M$36.30M$44.59M$62.36M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$0$297.00K$0UnavailableUnavailable$0$490.00K$842.00K$550.00K
Accounts receivable$32.00K$30.00K$33.00K$152.00K$0$0$111.00K$503.00K$883.00K$647.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.02M$1.64M$627.00K$331.00K$415.00K$281.00K$720.00K$628.00K$464.00K$1.17M

Cash flow

VivoSim Labs, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Operating cash flow-$10.83M-$9.46M-$14.65M-$12.41M-$8.45M-$13.32M-$14.88M-$20.38M-$28.86MUnavailable
Capital expenditures$0$13.00K$42.00K$396.00K$409.00K$405.00K$0$79.00K$226.00K$1.35M
Investing cash flow$94.00K$9.02M$816.00K-$966.00K-$409.00K-$393.00K$747.00K-$76.00K-$292.00KUnavailable
Financing cash flow$4.44M$8.85M$1.44M$0$205.00K$23.84M$4.94M$13.15M$10.11MUnavailable
Net change in cash-$6.29M$8.41M-$12.40M-$13.37M-$8.66M$10.12M-$9.20M-$7.30M-$19.02M$660.00K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$6.90M$7.39M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable$0$1.00K$0UnavailableUnavailableUnavailable
Depreciation & amortization$215.00K$266.00K$280.00K$293.00K$142.00K$41.00K$1.14M$980.00K$1.27M$1.15M

Derived

VivoSim Labs, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Free cash flow-$10.83M-$9.47M-$14.70M-$12.80M-$8.86M-$13.73M-$14.88M-$20.45M-$29.08MUnavailable
Gross margin100.0%96.5%UnavailableUnavailableUnavailableUnavailable86.3%83.8%78.3%77.4%
Operating margin-8768.7%-8761.1%-13840.4%-4792.2%-765.3%Unavailable-977.9%-882.4%-766.3%-911.9%
FCF margin-8264.9%-6579.2%-13481.7%-3460.5%-590.8%Unavailable-677.7%-661.7%-631.8%Unavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable174.8%
Current ratio2.38x3.25x2.12x4.64x21.35x53.26x15.65x10.32x10.04x10.83x
Revenue YoY growth-9.0%32.1%-70.5%-75.3%Unavailable-100.0%-29.0%-32.8%8.8%Unavailable
Net margin-10567.2%-1727.8%-13459.6%-4664.6%-763.2%Unavailable-852.0%-861.7%-756.1%-908.9%
R&D / revenue3197.7%3489.6%5044.0%2401.4%221.3%Unavailable240.6%477.3%390.1%462.1%
CapEx / revenue0.0%9.0%38.5%107.0%27.3%Unavailable0.0%2.6%4.9%32.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VIVS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-K · Filed 2026-07-14View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K · Filed 2025-06-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2021-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.